Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ABBV

Abbvie Inc

Dec 07 • 03:34PM ET

147.68

Dollar change +1.30
Percentage change 0.89	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	S&P 500	P/E	40.42	EPS (ttm)	3.65	Insider Own	0.14%	Shs Outstand	1.77B	Perf Week	3.72%
Market Cap	260.73B	Forward P/E	13.23	EPS next Y	11.16	Insider Trans	-3.08%	Shs Float	1.76B	Perf Month	3.88%
Income	6.48B	PEG	-	EPS next Q	2.90	Inst Own	71.26%	Short Float / Ratio	0.63% / 2.28	Perf Quarter	-0.90%
Sales	55.14B	P/S	4.73	EPS this Y	-18.53%	Inst Trans	0.10%	Short Interest	11.15M	Perf Half Y	7.29%
Book/sh	6.85	P/B	21.56	EPS next Y	-0.50%	ROA	4.67%	Target Price	169.47	Perf Year	-9.80%
Cash/sh	7.53	P/C	19.62	EPS next 5Y	-4.18%	ROE	46.15%	52W Range	130.96 - 168.11	Perf YTD	-8.62%
Dividend	5.69	P/FCF	10.54	EPS past 5Y	14.96%	ROI	9.57%	52W High	-12.15%	Beta	0.46
Dividend %	3.85%	Quick Ratio	0.84	Sales past 5Y	16.27%	Gross Margin	71.14%	52W Low	12.77%	ATR	2.42
Employees	50000	Current Ratio	0.96	Sales Q/Q	-5.97%	Oper. Margin	38.37%	RSI (14)	70.10	Volatility	1.91% 1.57%
Optionable	Yes	Debt/Eq	5.02	EPS Q/Q	-54.92%	Profit Margin	11.75%	Rel Volume	0.97	Prev Close	146.38
Shortable	Yes	LT Debt/Eq	4.60	Earnings	Oct 27 BMO	Payout	86.17%	Avg Volume	4.90M	Price	147.68
Recom	2.11	SMA20	5.47%	SMA50	2.71%	SMA200	0.46%	Volume	4,472,340	Change	0.89%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-09-23	Initiated	Deutsche Bank	Hold	$150
Oct-30-23	Upgrade	Barclays	Equal Weight → Overweight	$160 → $170
Oct-20-23	Resumed	UBS	Neutral	$157 → $150
Sep-29-23	Initiated	Raymond James	Outperform	$177
Jul-25-23	Initiated	William Blair	Mkt Perform
Jul-14-23	Initiated	HSBC Securities	Buy	$167
Apr-05-23	Downgrade	Argus	Buy → Hold
Mar-01-23	Initiated	Guggenheim	Buy	$172
Feb-22-23	Downgrade	Wolfe Research	Outperform → Peer Perform
Feb-10-23	Upgrade	SVB Securities	Underperform → Market Perform	$135 → $153
Nov-18-22	Initiated	Credit Suisse	Outperform	$170
Nov-08-22	Downgrade	Societe Generale	Buy → Hold
Aug-01-22	Downgrade	Atlantic Equities	Overweight → Neutral	$178 → $162
May-23-22	Initiated	SVB Leerink	Underperform	$140
May-06-22	Downgrade	Daiwa Securities	Outperform → Neutral	$150
Apr-06-22	Resumed	Morgan Stanley	Overweight	$192
Feb-28-22	Downgrade	UBS	Buy → Neutral	$129 → $147
Feb-03-22	Reiterated	Goldman	Neutral	$117 → $122
Feb-03-22	Reiterated	BofA Securities	Neutral	$135 → $138
Feb-03-22	Reiterated	BMO Capital Markets	Outperform	$153 → $154

Show Previous Ratings

Today 02:03PM	FTC warns pharma companies on excessive drug patenting (Yahoo Finance Video)
01:34PM	AbbVie's $8.7 billion bet on Cerevel is risky but smart, analysts say (Reuters)
01:30PM	AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say (Reuters)
01:27PM	AbbVie Dividend Secure Despite Deal-Making (Barrons.com)
12:35PM	Bain scores over tenfold return with $8.7 billion Cerevel sale (Reuters)
11:46AM	Loading…
11:46AM	Analyst Report: AbbVie Inc. (Morningstar Research)
11:13AM	AbbVie CEO Gonzalez brushes off FTC concerns for Cerevel buy: 'This acquisition is not anti-competitive.' (FierceBiotech.com)
11:06AM	AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion (CNBC TV)
10:04AM	AbbVie acquiring Cerevel Therapeutics in $8.7B deal (Yahoo Finance Video)
09:51AM	AbbVie to focus on smaller deals after buying spree (Reuters)
07:51AM	AbbVie Is Buying Cerevel Therapeutics, Which I Recommended Last Month. Now What? (TheStreet.com)
07:49AM	5 Things to Know Before Markets Open (Investopedia)
06:05AM	Is AbbVie Stock a Buy Now? (Motley Fool)
05:50AM	Which Stock Is More Likely to Help You Retire as a Millionaire: AbbVie or Eli Lilly? (Motley Fool)
05:38AM	AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B (Zacks)
05:33AM	Loading…
05:33AM	AbbVie Makes Another Big Pharma Acquisition. How Its Putting Its Cash to Work. (Barrons.com)
05:00AM	Looking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now. (Motley Fool)
01:44AM	PRESS DIGEST- Wall Street Journal - Dec. 7 (Reuters)
Dec-06-23 10:33PM	Cerevel options trading surge before AbbVie deal news raises eyebrows (Reuters)
06:23PM	AbbVie to buy drug developer Cerevel for $8.7 billion (Reuters)
05:20PM	AbbVie pads neuroscience portfolio with $8.7B deal to acquire Cerevel (FierceBiotech.com)
04:46PM	AbbVie to Buy Cerevel Therapeutics for $8.7 Billion (The Wall Street Journal)
04:42PM	UPDATE 4-AbbVie to buy drug developer Cerevel for $8.7 billion (Reuters)
04:30PM	AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline (PR Newswire)
04:08PM	Exclusive-AbbVie nears roughly $8 billion deal for drug developer Cerevel-sources (Reuters)
12:15PM	AbbVie to buy Cerevel in $8.7B bet on brain drugs (BioPharma Dive)
10:02AM	15 Best Safe Dividend Stocks For 2024 (Insider Monkey)
09:19AM	Pharma Stocks With Nice Dividends: The RX Investors Need (Barrons.com)
Dec-05-23 11:15AM	12 Best Healthcare Dividend Stocks To Buy Now (Insider Monkey)
09:00AM	AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:45AM	Loading…
08:45AM	AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies (PR Newswire)
Dec-04-23 11:00PM	Here's Why AbbVie (ABBV) Rose in Q3 (Insider Monkey)
06:07AM	AbbVie agrees to acquire ImmunoGen for around $10.1bn (Pharmaceutical Business Review)
Dec-02-23 10:00AM	2 Dividend Stocks to Buy and Hold Forever (Motley Fool)
07:30AM	5 S&P 500 Stocks That Pay a Generous Dividend (Motley Fool)
Dec-01-23 09:58AM	CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q3 2023 Earnings Call Transcript (Insider Monkey)
05:55AM	AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion (Zacks)
Nov-30-23 09:51PM	AbbVie Stock (NYSE:ABBV): Bet on a Smart Drugmaker and Dealmaker (TipRanks)
07:19PM	Why Abbvie Stock Popped Today (Motley Fool)
04:22PM	AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal (Investor's Business Daily)
03:48PM	AbbVie to acquire ImmunoGen in $10B deal (Yahoo Finance Video)
01:59PM	ImmunoGen Stock Soars 81% on AbbVies $10.1 Billion Takeover (Barrons.com)
01:43PM	Analyst Report: AbbVie Inc. (Morningstar Research)
11:56AM	AbbVie (ABBV) Posts Encouraging Data From Lung Cancer Study (Zacks)
11:49AM	AbbVie Pays $10.1 Billion for ImmunoGen to Expand Its Cancer Drug Portfolio (Investopedia)
10:37AM	AbbVie to Buy Cancer Biotech ImmunoGen for More Than $10 Billion (The Wall Street Journal)
09:44AM	Biotech Stocks Rally After $10.1 Billion ImmunoGen Buyout (The Wall Street Journal)
08:19AM	Drugmaker AbbVie to spend over $10B on ImmunoGen to juice its cancer-fighting treatment portfolio (Associated Press Finance)
08:18AM	AbbVie to Acquire ImmunoGen in $10 Billion Deal (Barrons.com)
08:15AM	AbbVie Should Consider a Dividend Cut -- Here's Why (Motley Fool)
07:51AM	AbbVie to Buy ImmunoGen for More Than $10 Billion (The Wall Street Journal)
07:45AM	AbbVie seeks lift from 'guided missile' cancer drug with $10 billion ImmunoGen deal (Reuters)
07:41AM	UPDATE 3-AbbVie signs $10 bln deal to buy cancer drugmaker ImmunoGen (Reuters)
07:33AM	AbbVie to buy ImmunoGen for $10.1 billion (Reuters)
07:30AM	AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio (PR Newswire)
05:31AM	AbbVie's lung cancer data light path to ADC accelerated approval but fall short of earlier benchmark (FierceBiotech.com)
Nov-29-23 08:45AM	AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC) (PR Newswire)
Nov-28-23 11:32AM	AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag (Zacks)
05:05AM	Pharma benefited from basing business overseas. An international tax effort could spur a rethink. (BioPharma Dive)
Nov-27-23 07:00AM	AbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY/TEPKINLY) for the Treatment of Relapsed/Refractory Follicular Lymphoma (PR Newswire)
06:03AM	Invest with Confidence: Intrinsic Value Unveiled of AbbVie Inc (GuruFocus.com)
Nov-26-23 06:55AM	3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later (Motley Fool)
06:47AM	5 Best Drug Stocks To Invest In (Insider Monkey)
05:38AM	11 Best Halal Dividend Stocks To Buy (Insider Monkey)
Nov-24-23 09:00AM	AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:45AM	Could AbbVie Stock Help You Become a Millionaire? (Motley Fool)
03:49AM	Goldman Sachs Value Stocks: Top 12 Stock Picks (Insider Monkey)
Nov-21-23 09:30AM	Should You Invest in AbbVie (ABBV) Based on Bullish Wall Street Views? (Zacks)
05:53AM	MorphoSys, after saying AbbVie 'failed', defends own mixed blood cancer data, plots approval filings (FierceBiotech.com)
05:50AM	3 "Boring" Stocks That Could Make You Rich (Motley Fool)
05:30AM	Ignore Eli Lilly. These 2 Stocks Are Better Buys Right Now (Motley Fool)
Nov-20-23 10:08AM	12 Best Stocks to Buy and Hold for a Lifetime (Insider Monkey)
08:45AM	Fifth Annual BOTOX Cosmetic (onabotulinumtoxinA) Day Makes History as the Biggest Day Ever (PR Newswire)
06:52AM	20 Most Valuable Healthcare Companies in the World (Insider Monkey)
Nov-19-23 08:12AM	Dividend Champions List Ranked By Yield: Top 30 (Insider Monkey)
Nov-17-23 10:32AM	13 Cheap Monthly Dividend Stocks to Buy (Insider Monkey)
Nov-16-23 07:00AM	Results Published in The Lancet Show UBRELVY (ubrogepant) Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of Migraine (PR Newswire)
05:00AM	AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell? (Motley Fool)
Nov-14-23 05:36AM	2 High-Yield Dividend Stocks You Can Buy Now and Hold for a Decade (Motley Fool)
05:30AM	3 Dividend Giants to Grow Wealth no Matter What the Market Is Doing (Motley Fool)
Nov-13-23 09:50PM	Jim Simons Stock Portfolio: 12 Biggest Healthcare Stocks (Insider Monkey)
05:00PM	12 Stocks from Companies Generating High Cash Flow (Insider Monkey)
04:05PM	NEXGEL Reports Record Third Quarter 2023 Revenue of $1.2 Million, an Increase of 115% Year-Over-Year (GlobeNewswire)
02:56PM	10 Healthcare Focused Hedge Funds and 10 Top Stock Picks (Insider Monkey)
02:14PM	Dividend Kings Ranked By Yield: Top 25 (Insider Monkey)
09:00AM	Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know (Zacks)
06:02AM	Navigating Market Uncertainty: Intrinsic Value of AbbVie Inc (GuruFocus.com)
Nov-11-23 06:50AM	3 Growth Stocks to Buy Right Now Without Any Hesitation (Motley Fool)
Nov-10-23 07:45AM	5 Best DRIP Stocks To Own (Insider Monkey)
05:00AM	AbbVie's $21 Billion Drug Humira Is on the Decline. Should You Still Buy This Dividend Stock? (Motley Fool)
Nov-08-23 08:45AM	Natrelle Unveils New 'For Every BODY' Campaign (PR Newswire)
06:55AM	FTC challenges patents held by nine big drugmakers, citing unfair competition (BioPharma Dive)
Nov-07-23 11:29AM	U.S. FTC disputes Orange Book listing for some drug patents (Reuters)
Nov-05-23 10:00AM	3 Spectacular High-Yield Dividend Stocks to Buy in November (Motley Fool)
Nov-04-23 05:30AM	Looking for a Lifetime of Passive Income? 2 Top Dividend Stocks to Buy and Hold Forever (Motley Fool)
Nov-03-23 08:46AM	Morphic Holding Inc (MORF) Reports Q3 2023 Loss of $36.2 Million, Ends Quarter with $725. ... (GuruFocus.com)
05:32AM	Is AbbVie Stock a Buy Now? (Motley Fool)
Nov-02-23 09:00AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
08:31AM	Roundhill Investments Launches Dividend Monarchs ETF (NYSE Arca: KNGS) (PR Newswire)
08:30AM	3 Dividend Stocks That Can Power Your Portfolio for Decades (Motley Fool)

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GONZALEZ RICHARD A	CHAIRMAN OF THE BOARD AND CEO	Aug 01	Sale	148.58	60,000	8,914,800	565,294	Aug 02 05:07 PM
GONZALEZ RICHARD A	CHAIRMAN OF THE BOARD AND CEO	Jul 31	Sale	149.15	18,500	2,759,275	625,294	Aug 02 05:07 PM
Sorg Elaine K.	SVP, US COMMERCIAL OPERATIONS	Apr 25	Option Exercise	144.54	6,130	886,030	41,460	Apr 27 05:00 PM
Sorg Elaine K.	SVP, US COMMERCIAL OPERATIONS	Apr 25	Sale	165.00	6,130	1,011,450	35,330	Apr 27 05:00 PM
Sorg Elaine K.	SVP, US COMMERCIAL OPERATIONS	Apr 17	Sale	161.67	7,499	1,212,338	35,330	Apr 19 05:00 PM
Sorg Elaine K.	SVP, US COMMERCIAL OPERATIONS	Apr 03	Option Exercise	93.50	15,002	1,402,687	57,831	Apr 05 05:00 PM
Siatis Perry C	EVP, GC AND SECRETARY	Apr 03	Option Exercise	105.92	3,520	372,838	13,897	Apr 05 05:00 PM
Sorg Elaine K.	SVP, US COMMERCIAL OPERATIONS	Apr 03	Sale	160.03	15,002	2,400,770	42,829	Apr 05 05:00 PM
Siatis Perry C	EVP, GC AND SECRETARY	Apr 03	Sale	160.00	3,520	563,200	10,377	Apr 05 05:00 PM
Stewart Jeffrey Ryan	EVP, CHIEF COMMERCIAL OFFICER	Mar 13	Option Exercise	54.86	21,810	1,196,497	114,066	Mar 15 05:00 PM
Stewart Jeffrey Ryan	EVP, CHIEF COMMERCIAL OFFICER	Mar 13	Sale	152.28	53,125	8,089,998	60,941	Mar 15 05:00 PM
Sorg Elaine K.	SVP, US COMMERCIAL OPERATIONS	Mar 01	Option Exercise	93.50	15,003	1,402,780	57,832	Mar 02 05:07 PM
SALEKI-GERHARDT AZITA	EVP, OPERATIONS	Mar 01	Option Exercise	51.42	26,990	1,387,826	226,839	Mar 02 05:01 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Mar 01	Sale	153.28	44,141	6,766,103	13,837	Mar 02 04:30 PM
SALEKI-GERHARDT AZITA	EVP, OPERATIONS	Mar 01	Sale	154.48	36,990	5,714,215	189,849	Mar 02 05:01 PM
Reents Scott T	EVP, CHIEF FINANCIAL OFFICER	Mar 01	Sale	153.08	15,942	2,440,355	809	Mar 02 05:04 PM
Sorg Elaine K.	SVP, US COMMERCIAL OPERATIONS	Mar 01	Sale	155.00	15,003	2,325,465	42,829	Mar 02 05:07 PM
Siatis Perry C	EVP, GC AND SECRETARY	Mar 01	Sale	153.08	12,135	1,857,641	10,377	Mar 02 05:06 PM
Sorg Elaine K.	SVP, US COMMERCIAL OPERATIONS	Feb 21	Option Exercise	105.92	15,321	1,622,800	78,000	Feb 21 06:12 PM
Strom Carrie C	SVP & PRES GLOBAL ALLERG AESTH	Feb 21	Option Exercise	61.57	14,179	872,949	66,462	Feb 21 06:14 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 21	Option Exercise	93.50	7,364	688,534	39,532	Feb 22 05:00 PM
Strom Carrie C	SVP & PRES GLOBAL ALLERG AESTH	Feb 21	Sale	151.04	28,541	4,310,771	37,921	Feb 21 06:14 PM
Sorg Elaine K.	SVP, US COMMERCIAL OPERATIONS	Feb 21	Sale	151.04	15,321	2,314,119	62,679	Feb 21 06:12 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 21	Sale	151.03	7,364	1,112,178	32,168	Feb 22 05:00 PM
SALEKI-GERHARDT AZITA	EVP, OPERATIONS	Feb 17	Option Exercise	51.42	25,000	1,285,500	258,208	Feb 21 06:13 PM
SALEKI-GERHARDT AZITA	EVP, OPERATIONS	Feb 17	Sale	149.53	25,000	3,738,144	233,208	Feb 21 06:13 PM
AUSTIN ROXANNE S	Director	Feb 17	Sale	150.50	10,000	1,505,000	40,705	Feb 21 06:16 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Dec 12	Option Exercise	54.86	42,370	2,324,418	56,207	Dec 14 05:06 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Dec 12	Sale	163.44	42,370	6,925,018	13,837	Dec 14 05:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABBV

Abbvie Inc

Upgrade your FINVIZ experience